The cardiac-enriched isoform of acetyl-CoA carboxylase (ACC2) is a key regulator of mitochondrial fatty acid (FA) uptake via carnitine palmitoyltransferase 1 (CPT1). In order to test the hypothesis that oxidative metabolism is upregulated in hearts from animals lacking ACC2 (employing a transgenic Acc2-mutant mouse) we assessed cardiac function in vivo and determined rates of myocardial substrate oxidation ex vivo. When examined by echocardiography there was no difference in systolic function, but left ventricular mass of the Acc2-mutant (MUT) mouse was significantly reduced (~25%) compared to wildtypes (WT). Reduced activation of the mammalian target of rapamycin (mTOR) and its downstream target p70S6K was found in MUT hearts. Exogenous oxidation rates of oleate were increased ∼22%, and, unexpectedly, exogenous glucose oxidation rates were also increased in MUT hearts. Using a hyperinsulinemic-euglycemic clamp, we found that glucose uptake in MUT hearts was increased by ~83%. Myocardial triglyceride levels were significantly reduced in MUT versus wildtypes while glycogen content was the same. In parallel, transcript levels of PPARα and its target genes, pyruvate dehydrogenase kinase-4 (PDK-4), malonyl-CoA decarboxylase (MCD) and mCPT1 were downregulated in MUT mice. In summary, we report that: 1) Acc2-mutant hearts exhibit a marked preference for the oxidation of both glucose and fatty acids coupled with greater utilization of endogenous fuel substrates (triglycerides); 2) Attenuated mTOR signaling may result in reduced heart sizes observed in Acc2-mutant mice; and 3) Acc2-mutant hearts displayed normal functional parameters despite a significant decrease in size, (240 words) 3
ABSTRACT
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INTRODUCTION
Carnitine palmitoyltransferase 1 (CPT1), which catalyzes the rate-limiting step of mitochondrial fatty acid (FA) uptake, is subject to stringent regulatory mechanisms (24).
Malonyl-CoA is a potent allosteric inhibitor of CPT1 and acts as a rheostat for overall mitochondrial FA β-oxidation (FAO) (26). Malonyl-CoA levels are controlled by its rates of synthesis (via acetyl-CoA carboxylase [ACC] ) and rates of degradation (via malonylCoA decarboxylase [MCD] ). Of the two ACC isoforms, ACC1 (≈ 265-kDa) is predominantly expressed in lipogenic tissues such as the liver and adipocytes (1, 23, 36) , while ACC2 (≈ 280-kDa) is enriched in tissues with enhanced oxidative capacity for e.g. heart and skeletal muscle (2, 8, 37) . The distinct ACC isoform expression profiles suggest that malonyl-CoA generated by ACC1 and ACC2 may differentially regulate FA synthesis and FAO. In support, we presented evidence for separate ACC subcellular locations, with ACC1 localized to the cytosol and ACC2 associated with mitochondria (3) . Moreover, Acc2-mutant mice (lacking functional ACC2) displayed increased FAO rates in skeletal muscle, and reduced body weight and fat content (4) . On the contrary, a null mutation of ACC1 in mice resulted in embryonic lethality (6) .
Recently, we found that Acc2-mutant mice, unlike wildtype controls, did not develop diabetes when fed an obesity-inducing diet (5) . Moreover, Debard et al. (13) reported increased ACC2 gene expression levels in skeletal muscle of Type 2 diabetic patients. Together these data suggest that high levels of ACC2 may contribute to the development of the diabetic phenotype, and that diminished ACC2 expression in this particular context may hold therapeutic value. In light of these observations, we investigated the effects of in vivo ACC2 lack on the regulation of myocardial fuel substrate oxidation. In this study, we performed Langendorff heart perfusions comparing the previously described Acc2-mutant transgenic mouse strain (4) with age-matched controls, and matched substrate oxidation data with expression levels of cardiac metabolic genes and functional data generated by echocardiography. Here we found that both myocardial oleate and glucose oxidation rates were higher in Acc2-mutant mice, associated with sustained cardiac contractile function, but reduced heart size.
Reduced activation of the mammalian target of rapamycin (mTOR) and its downstream target p70S6K was found in MUT hearts and may account for its decreased size. In parallel, expression of peroxisome proliferator-activated receptor-alpha (PPARα) and its target genes was attenuated in Acc2-mutant mice compared to controls. We propose that this may help sustain normal function of the Acc2-mutant mouse heart. Measurement of myocardial malonyl-CoA levels. Heart tissue was harvested, snap-frozen in liquid nitrogen and then homogenized in a 1:10 volume (w/v) of ice-cold 5% sulfosalicylic acid containing 50 µM dithioerythritol. Homogenates were centrifuged at 15, 000g for 60 min at 2°C and the supernatants filtered through a 0.22 micron filter (Ultrafree-MC, Millipore Corporation, Bedford, MA). Samples were stored at -80°C prior to liquid chromatography mass spectrometry analysis. HPLC was run in binary mode [A:
METHODS

Animals. Generation of the
5 mM dimethylbutylamine and 6 mM HOAc; B: 0.1% formic acid in CH3CN (EMD Chemicals, Gibbstown, NJ)] at 200 mL/min with the third pump to deliver post column mixing solvent CH3CN. The data were acquired on an Applied Biosystem Pulsar I quadrapole-TOF mass spectrometer (Foster City, CA) using positive ion TOFMS mode.
Measurement of myocardial triglyceride levels.
Heart triglyceride levels were measured as described by Chandler et al. (11) . Hearts (n=5), were excised, washed with PBS and stored in -80ºC before being processed. Individual hearts were homogenized using a Kinematica Polytron mechanical tissue blender for 30 secs (medium speed), followed by extraction with 2 volumes of chloroform: methanol (1:1).
The organic fraction was evaporated using nitrogen, and the pellet dissolved in 1% Triton X-100 (diluted in ethanol). Samples were diluted 1:5 and triglyceride levels measured using the Infinity Triglyceride Kit (Thermo Electron, Rugby, UK) that was adapted for colorimetric analysis in 96-well plate format.
Measurement of myocardial glycogen levels.
Wild type and Acc2-mutant mice (n=5) were killed by decapitation, hearts rapidly isolated and immediately frozen in liquid nitrogen. Myocardial glycogen levels were determined using the method of Hassid and Abraham (19). Frozen hearts were placed in test tubes and dissolved in 30% KOH (w/v) whereafter tubes were immersed in boiling water and glycogen precipitated with ethanol.
Glycogen was converted to monosaccharides by boiling the pellet in 1 ml of 3.79 M H 2 SO 4 for 3 hrs followed by the addition of 0.1 ml 0.33 M MOPS. The solution was thereafter neutralized to pH 7 using 10 M KOH. The final volume was recorded and glucose concentration measured using a glucose-determining kit (Sigma, St. Louis, MO).
Glycogen content was expressed as mg glucose/gram (wet weight).
Determination of ex vivo cardiac fuel substrate metabolism. Five-month old male
Acc2-mutant and matched wildtype mice were anesthetized with chloral hydrate (0. Data were normalized to the number of cyclophilin transcripts, which was not significantly different between the treatment groups (data not shown).
Preparation of mitochondrial fractions. Mitochondria-enriched fractions were obtained from wildtype and mutant mouse hearts as previously described (31), with minor modifications. Hearts (3-4 animals) were homogenized in 250 mM sucrose buffer using an omni mixer and subsequently centrifuged at 1, 000g for 15 min. The pellet was homogenized and centrifuged at 600g for 10 min. The resulting supernatant was centrifuged at 15, 000g for 15 min, and the pellet resuspended in 100 µl of a buffer containing 250 mM sucrose and 150 mM KCl. All manipulations were performed at 4°C.
Mitochondrial protein concentrations were determined using the Bio-Rad protein assay with bovine albumin as a standard.
To determine steady-state peptide levels of mitochondrial mCPT1, 30 µg of mitochondrial protein were subjected to polyacrylamide gel electrophoresis (4-12% NuPAGE MES gels). Mitochondrial mCPT 1 peptide levels were detected using an antibody kindly provided by Dr. VA Zammit (Warwick Medical School, Coventry, UK). For equal loading controls, the same blot was stripped, washed and probed with avidin peroxidase that detects mitochondrial biotinylated proteins such as propionyl-CoA carboxylase (PCC), which was equally expressed in hearts of wildtype and Acc2-mutant mice.
Total protein isolation and immunoblotting. Hearts from wildtype and mutant Acc2 mice were excised, snap-frozen and ground in liquid nitrogen. This powder was added to a homogenization buffer consisting of: 3 ml of RIPA buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 1% NP-40; 0.5% deoxy cholic acid; 0.1% SDS; 1 mM NaVO 3 ; 10 mM NaF; 0.2 mM EDTA; protease inhibitor cocktail [1 mM PMSF, and 3 µg/ml of leupeptine, pepstatin, aprotinin and anti-trypsin]. The suspension was homogenized using a Polytron for 30 sec followed by 3x 10 sec sonication bursts. The lysate was thereafter centrifuged at 27,000g for one hour. Protein concentrations were determined and 30 µg of each sample separated on 4-12% NuPAGE MES gels. 
Relative wall thickness was calculated as 2*Posterior wall diastole /LV diameter diastole . Heart rate was determined from at least three consecutive intervals from the pulse wave Doppler tracings of the LV outflow tract. Isovolumic relaxation time was measured as the time from the closing of the aortic value to the opening of the mitral value from pulse wave Doppler tracings of the LV outflow tract and mitral inflow region. To measure E and A waves heart rates were slowed down using additional doses (1/4 to 1/2) of ketamine.
However, all other measurements (except E and A waves) were performed at the higher heart rate. For tissue Doppler measures, the smallest possible sample volume was placed at the septal mitral annulus to capture the early diastolic (Ea) and late diastolic were anesthetized with pentobarbital sodium injection and tissues were taken for biochemical measurements within 3 min. For the determination of heart glucose uptake, heart samples were homogenized, and the supernatants were subjected to an ionexchange column to separate tissue 14 C-2-DG-6-phosphate (2-DG-6-P) from 2-DG.
Heart glucose uptake was calculated from the area under the curve of the plasma 14 C-2-DG profile and muscle 14 C-2-DG-6-P content, as previously described (40).
Statistical analysis. The time course data for the heart perfusion studies are presented as means ± SE. Statistical analysis on perfusion data was performed using ANOVA repeated measures one-way analysis of variance. The unpaired Student's t-test was used to determine differences between two groups. A value of P < 0.05 was considered significant.
RESULTS
In vivo cardiac functional analysis. Echocardiographic studies were performed and data are summarized in Table 1 . There was a ∼25% decrease in LV mass and LV mass/body weight, consistent with a smaller heart as assessed by dry weight measurement during the metabolic studies. In Acc2-mutant mice, LV diastolic and LV systolic dimensions decreased by 17 and 27% respectively, compared to wildtypes (P < 0.001). The decrease in both LV dimensions did not cause a significant change in fractional shortening (45 ± 5 and 38 ± 12 in Acc2-mutant mouse and matched controls, respectively) ( Table 1) . Although there was a slight increase in the heart rate of Acc2-mutant mice, this did not reach statistical significance (530 ± 82 and 578 ± 61 beats/min for wildtype and Acc2-mutant mice, respectively). When additional ketamine was administered to measure E and A waves the heart rate decreased to 316 ± 51 and 325 ± 32 beats/min for wildtype and mutant mice, respectively. All other parameters such as PWd, Awd RWth, E/A, Ea/Aa and IVRT were similar (Table 1) .
Heart weight. We also determined the heart dry weight of mice at the end of perfusion studies. Interestingly, heart weight (29 ± 2 vs. 48 ± 4 mg; n = 8, p= 0.001) and the heart/body weight ratio were significantly reduced in mutant versus wildtype mice (0.94 ± 0.01 vs. 1.27 ± 0.11; n = 8; P < 0.05) (Fig.1) . These results are consistent with our echocardiography studies, confirming reduced heart size in Acc2-mutant mice.
Determination of myocardial malonyl-CoA and MCD levels. Malonyl-CoA levels
in Acc2-mutant hearts were markedly reduced (∼70%) compared to wildtypes (P = 0.0001) ( Fig. 2A) . These levels are consistent with previous measurements in Acc2- mRNA/protein levels in heart tissues compared to ACC1 (1, 2, 37). Since MCD is also a major regulator of malonyl-CoA levels in muscle and heart tissues, we also measured MCD expression levels. Here, MCD transcript levels were reduced by ~50% in Acc2-mutant hearts compared to wild types (data not shown). In agreement, we found that MCD protein levels were also decreased (P = 0.001 vs. wild types) ( Fig. 2B and 2C ). As shown in Figure 2D , ACC1 is still expressed to a significant degree in Acc2-mutant hearts, suggesting that residual malonyl-CoA is due to both remaining ACC1 and MCD downregulation in mutant hearts. There were no significant changes in the level of two mitochondrial enzymes, i.e. propionyl-CoA carboxylase and pyruvate carboxylase (Fig.   2D ).
Determination of myocardial glycogen and triglyceride content. Endogenous triglycerides and glycogen are important myocardial energy sources. Here we found that glycogen levels were similar in hearts of wild type and Acc2-mutant mice (0.27 ± 0.04 and 0.29 ± 0.05 mg/g wet weight, respectively) (Fig. 3A) . However, myocardial triglyceride levels were markedly reduced in mutant hearts versus wildtypes (2.25 ± 0.35 and 1.16 ± 0.41 mg/g wet weight, respectively; P = 0.007) (Fig. 3B) . These results therefore suggest that Acc2-mutant mice do not spare glucose as glycogen.
Ex vivo cardiac fuel substrate oxidation rates. Myocardial oxygen uptake (MVO 2 )
was not statistically different in Acc2-mutant compared wildtypes (30 ± 4.9 and 22 ± 5.6
µmol/min.gr dry weight, respectively) ( Myocardial glucose uptake in vivo. We used hyperinsulinemic-euglycemic clamp conditions to determine glucose uptake in hearts. Consistent with the increase in glucose oxidation in isolated hearts of Acc2-mutant mice, the glucose uptake was ~83%
higher in Acc2-mutant hearts compared to the wildtypes (Fig. 6) .
Expression of genes regulating fatty acid and glucose metabolism. To gain further insight into mechanisms underlying myocardial fuel substrate utilization in the Acc2-mutant mouse strain, we measured transcript levels of the nuclear receptor PPARα, a transcription factor that regulates numerous genes involved in the uptake and oxidation of FAs. We found that PPARα transcript levels were significantly decreased in mutant versus wildtype mice (Table 2) . Transcript levels of two other PPARα-regulated genes, i.e. mCPT1 and MCAD also displayed downward trends. PGC-1α transcript levels did not significantly differ between mutant and wildtype strains.
The rate-limiting step for exogenous glucose utilization is its transport into cardiomyocytes via specific carrier-mediated transporters, i.e. GLUT1 and GLUT4.
Transcript levels of both transporters did not differ significantly between Acc2-mutant and wild type mice (Table 2) . However, transcript levels of PDK-4, an indirect inhibitor of glucose and lactate oxidation, were markedly downregulated in mutant versus wild type mice (Table 2) (n = 4, p <0.05).
Western blot analysis of mitochondrial protein extracts showed that mCPT1 expression was significantly reduced in the Acc2-mutant mouse heart compared to wildtypes (Fig. 7) . The densitometric analysis shows ~2x higher mCPT1 peptide levels in wildtype versus mutant hearts (Fig. 7) . These results are consistent with lower PPARα mRNA in hearts of Acc2-mutant mice shown in Table 2 .
To gain insight into mechanisms that may regulate the reduced heart size of Acc2-mutant mice, we determined peptide levels of members of the mTOR pathway, which is implicated in the control of protein translation. We found that mTOR levels were similar in both wildtype and mutant hearts (Fig. 8A) . However, phosphorylation of mTOR on Ser 2481 was significantly reduced in mutant hearts (P = 0.01 vs. wildtypes), suggesting decreased autophosphorylation and mTOR activity. Reduced mTOR phosphorylation was accompanied by a significant decrease in phosphorylation of its downstream target P70S6K (at Thr 389 ) (Fig. 8B ). There were no significant changes in Akt/pAKT levels ( Fig. 8C ), suggesting that down regulation of mTOR signaling in Acc2-mutant hearts does not involve the AKT pathway.
DISCUSSION
The main findings of this study are: 1) a reduced heart size in Acc2-mutant mice, without impaired cardiac function; 2) increased oxidation rates of both oleate and glucose in Acc2-mutant mouse heart; 3) increased glucose uptake in Acc2-mutant mouse heart and 4) downregulation of PPARα and its target genes in the Acc2-mutant mouse.
Reduced heart size in Acc2-mutant mouse. The heart mass of the Acc2-mutant mouse was significantly reduced compared to wildtypes (lower heart weight/body weight ratios). We confirmed this reduction in heart size by measuring the dry weight of hearts at the end of perfusion studies, which exhibited a ∼25-30% reduction in size. Moreover, echocardiographic analysis performed showed that left ventricular mass and the left ventricular wall diameter were significantly reduced in mutant versus wildtype mice.
However, echocardiography also revealed that contractile function was not altered in the Acc2-mutant mouse heart (Table 1) .
It is unclear why the heart size of the mutant mouse is reduced and what the precise regulatory mechanisms are. Here we propose that high fatty acid oxidation rates by the Acc2-mutant heart depletes myocardial diacylglycerol and phosphatidic acid content, thereby leading to reduced phosphorylation of mTOR and its downstream targets, i.e. p70S6K. This is in agreement with previous work showing that phosphatidic acid binds to the FRB domain of mTOR resulting in its activation (16 , suggesting a correlation between mTOR activity and phosphorylation of P706SK at the Thr 389 site (7) . We therefore propose that reduced mTOR signaling/activity will eventually result in the decreased heart size observed in the Acc2-mutant mouse.
Increased oxidation rates of exogenous oleate and glucose and higher glucose
uptake in Acc2-mutant mouse hearts. Because we had previously reported markedly reduced malonyl-CoA levels in the Acc2-mutant mouse heart (4), we predicted increased myocardial FAO rates. Here we found that myocardial malonyl-CoA levels were markedly reduced in mutant mice, and cardiac FAO rates accordingly increased compared to wildtypes. In agreement, we previously reported elevated FAO rates in isolated soleus muscle, hepatocytes and adipocytes due to lower malonyl-CoA levels found in the Acc2-mutant mouse (4, 5, 27). Although malonyl-CoA levels were reduced in mutant hearts, a residual amount nonetheless remained. We propose that this may be mainly due to lower MCD levels (also a PPARα target gene) and remaining ACC1 expression.
A major concern is the question of the effects of constitutively increased fat oxidation in the heart because more than 70% of cardiac energy production results from fat oxidation (9, 39), and originally fuel competition between fat and carbohydrate was observed in the heart (29). Moreover, it is well known that diabetic heart is characterized by increased fat oxidation and reduced glucose metabolism (21, 22, 30). The Acc2-mutant mice had a normal life span and did not exhibit obvious contractile impairment, which is supported by our current echocardiographic studies showing normal heart function. Intriguingly, we found that myocardial glucose oxidation rates in mutant mice were increased despite higher oleate oxidation rates. This increase in glucose oxidation appears to be mainly due to enhanced glucose uptake (Fig. 6 ). In accordance, we previously reported that adipose tissues of Acc2-mutant mice also displayed increased rates of glucose oxidation (4, 27). Moreover, our recently published study reported that Acc2-mutant mice displayed marked increases in insulin-stimulated whole body glucose uptake, glycolysis and skeletal muscle glucose uptake (12) . This is unexpected since the glucose-fatty acid cycle predicts that increased FAO rates should result in a corresponding reduction in glucose oxidation rates (29).
The amount of oxygen needed for complete oxidation of one mole of oleate and one mole of glucose is 24 and 6 moles, respectively. The combined oxidation of exogenous glucose and oleate (~600 nmol CO 2 /min/gr dry weight) is lower than the value for oxygen consumption (20-30, 000 nmol O 2 /min/gr dry weight). We propose that this may be due to increased breakdown of endogenous (triglycerides) and/or other exogenous fuel substrates (e.g. lactate, ketone bodies) that make a large contribution to the overall energy metabolism of mutant hearts. In agreement with this concept, we found that triglyceride levels were reduced in hearts of the Acc2-mutant mice. We also previously found that plasma β-hydroxybutyrate levels were significantly increased in the fed and fasted state of Acc2-mutant mice (12) . In addition, glycogen levels were similar in wildtype and Acc2-mutant hearts, suggesting that exogenous glucose supplied is oxidized rather than being stored as glycogen. Together our data suggest that Acc2-mutant hearts preferentially oxidize exogenous oleate and glucose, while endogenous fuel substrates such as triglycerides also make a greater contribution to overall oxidation rates compared to wildtypes. However, it is important to note that we are comparing oxidation rates of exogenous fuel substrates (supplied in perfusate) and that this may not necessarily correspond with the absolute myocardial oxidation rates of these substrates. Moreover, serum free fatty acid concentrations are in the nanomolar range;
hence cardiomyocytes rely on hydrolysis of circulating lipoproteins by lipoprotein lipase as the main source for fatty acid supply.
Reduced expression of PPARα and target genes in the Acc2-mutant mouse.
To gain further insight into these findings, we determined the expression of several cardiac metabolic genes. We found that myocardial transcript levels of PPARα, a well-described We propose that the lower PPARα and mCPT1 expression observed may be a compensatory mechanism to prevent excessively high myocardial FAO rates in the Acc2-mutant mouse strain. If such a control mechanism was indeed lacking, we predict that excessively high FAO rates could for example result in increased uncoupling of mitochondrial oxidative phosphorylation and reduced cardiac mitochondrial energy production. In agreement with this concept, a recent study investigating myocardial substrate metabolism of an MCD-deficient mouse found increased levels of PPARα gene expression associated with unchanged FA and glucose oxidation rates compared to controls (15) . Previously, we found reduced plasma free fatty acid (FFA) levels for Limitations. The ex vivo glucose oxidation rates reported in this study is lower than what has previously been reported from our laboratory and other studies (20, 33).
The perfusion data in the current study roughly translate to glucose oxidation contributing ∼20% of the energy production of wildtype hearts. We believe that this may be a strain-specific phenomenon related to the particular mouse strain we employed in this study. Also, the perfusion data were generated using a non-working heart system with low mechanic force and therefore the metabolic profile obtained using this model may not necessarily reflect what occurs in vivo. Thus although we carried out in vivo analyses of cardiac function, our findings would have been further strengthened by the inclusion of ex vivo heart functional analyses.
In conclusion, we report increased exogenous myocardial energy substrate utilization and lower levels of endogenous fuels (triglycerides) in Acc2-mutant hearts, associated with a reduction in heart size but normal cardiac function. We propose that attenuated mTOR signaling may be responsible for reduced heart size in mutant mice.
The fact that mutant hearts functioned normally despite the lack of a pivotal metabolic regulator (i.e. ACC2) is intriguing although underlying mechanisms are still unknown at this stage. Nonetheless, the study shows that ACC2 inhibition remains an attractive therapeutic target, despite continuously high myocardial FAO rates.
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Fig. 7. Representative Western blot of mCPT1 peptide levels.
Western Blot analysis of purified mitochondria and crude extracts (Methods) were separated by 4-12% NuPAGE MES gels. A) 30 µg protein of isolated mitochondria from heart and Acc2-mutant mice were subjected to electrophoresis gel separation. An antibody raised against rat muscle-type CPT1 was used to detect mouse mCPT1 by ECL (n=7). B) PCC peptide levels indicated as a control for loading in blot A). C)
Densitometric analysis was performed on mCPT1 blots using standard laboratory techniques and mCPT1 levels are given as wildtype/mutant ratio. 
